Inovio: Exciting News Published in The Lancet

Inovio Phase 1 Data of INO-4800 for COVID-19
Peer-reviewed Phase 1 data shows Inovio COVID-19 DNA Vaccine Candidate, INO-4800, to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses.

  • INO-4800 demonstrates favorable safety and tolerability.
  • No serious adverse events reported.
  • Offers best-in-class thermostability, including a five-year projected shelf life at normal refrigeration temperature and no frozen transport or storage requirements.

INOVIO (This content is for paid subscribers.

Please click here to subscribe or here to log in.